Essex Woodlands Management is an investment fund managing more than $307 billion ran by Gregory Hill. There are currently 7 companies in Mr. Hill’s portfolio. The largest investments include MiMedx Inc and Bioventus, together worth $270 billion.
As of 7th August 2024, Essex Woodlands Management’s top holding is 28,195,249 shares of MiMedx Inc currently worth over $195 billion and making up 63.7% of the portfolio value.
Relative to the number of outstanding shares of MiMedx Inc, Essex Woodlands Management owns less than 0.3% of the company.
In addition, the fund holds 13,021,324 shares of Bioventus worth $74.9 billion.
The third-largest holding is TELA Bio worth $19.3 billion and the next is EyePoint Pharmaceuticals Inc worth $13.5 billion, with 1,551,521 shares owned.
Currently, Essex Woodlands Management's portfolio is worth at least $307 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Essex Woodlands Management office and employees reside in The Woodlands, Texas. According to the last 13-F report filed with the SEC, Gregory Hill serves as the Chief Compliance Officer and Chief Financial Officer at Essex Woodlands Management.
In the most recent 13F filing, Essex Woodlands Management revealed that it had opened a new position in
Venus Concept and bought 1,089,190 shares worth $853 million.
This means they effectively own approximately 0.1% of the company.
Venus Concept makes up
0.4%
of the fund's Health Care sector allocation and has decreased its share price by 62.6% in the past year.
The investment fund also strengthened its position in MiMedx Inc by buying
4,779,665 additional shares.
This makes their stake in MiMedx Inc total 28,195,249 shares worth $195 billion.
MiMedx Inc dropped 15.9% in the past year.
On the other hand, there are companies that Essex Woodlands Management is getting rid of from its portfolio.
Essex Woodlands Management closed its position in Venus Concept on 14th August 2024.
It sold the previously owned 31,337,856 shares for $10 billion.
Gregory Hill also disclosed a decreased stake in EyePoint Pharmaceuticals Inc by 0.6%.
This leaves the value of the investment at $13.5 billion and 1,551,521 shares.
The two most similar investment funds to Essex Woodlands Management are Princeton Capital Management and Capital Planning. They manage $307 billion and $307 billion respectively.
Essex Woodlands Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 75.6% of
the total portfolio value.
The fund focuses on investments in the United States as
71.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
29% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $375 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| MiMedx Group, Inc |
20.41%
28,195,249
|
$195,393,076,000 | 63.71% |
| Bioventus |
7.64%
13,021,324
|
$74,872,613,000 | 24.41% |
| TELA Bio, Inc. |
No change
4,110,709
|
$19,320,332,000 | 6.30% |
| EyePoint Pharmaceuticals Inc |
62.98%
1,551,521
|
$13,498,233,000 | 4.40% |
| Venus Concept Inc. |
Closed
31,337,856
|
$10,028,114,000 | |
| Medicinova Inc |
No change
1,105,941
|
$1,592,555,000 | 0.52% |
| Revance Therapeutics Inc |
No change
457,085
|
$1,174,708,000 | 0.38% |
| Venus Concept Inc. |
Opened
1,089,190
|
$852,836,000 | 0.28% |
| No transactions found | |||
| Showing first 500 out of 8 holdings | |||